Exploring heterogeneity in survival benefit of neoadjuvant therapy for triple-negative breast cancer using causal survival forests.
INTRODUCTION The individual survival benefit of neoadjuvant therapy (NAT) for patients with triple-negative breast cancer (TNBC) remains uncertain. This study aimed to evaluate the individualized treatment effect (ITE) of NAT on event-free survival (EFS) in patients with TNBC using causal survival forests. METHODS Th...